Five Prime Therapeutics, Inc. (FPRX)

Oncology Corporate Profile

Stock Performance


HQ Location

Two Corporate Drive
South San Francisco, CA 94080

Company Description

Five Prime Therapeutics, Inc. is a clinical stage biotech company discovering innovative protein and antibody therapeutics using its world-class discovery platform. The Company is using this platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
FPA144FGFR2b antibodyBladder cancerI
FPA144FGFR2b antibodyGastric cancerI
FP-1039fibroblast growth factor receptor 1 (FGFR1) antagonistMesotheliomaI
FP-1039fibroblast growth factor receptor 1 (FGFR1) antagonistNon Small Cell Lung Cancer (NSCLC)I
cabiralizumab / FPA008 (+nivolumab)CSF-1R antibodyVarious cancer typesIBristol-Myers Squibb

View additional information on product candidates here »


Recent News Headlines

Novartis CEO Sees Tougher U.S. Drug Pricing over next Three-Five Years

10/25/2016 05:36 pm

(Reuters) Oct 25, 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.

Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types

10/4/2016 05:22 pm

(Yahoo! Finance) Oct 4, 2016 - Five Prime Therapeutics, Inc. today announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab (FPA008), Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), with OPDIVO® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, in multiple tumor types.

Study: Five-Year Survival Data Suggest Brentuximab Vedotin Potentially Curative in Some Hodgkin Lymphoma Patients with Limited Treatment Options

7/18/2016 03:57 pm

(ASH) July 18, 2016 - Five-year survival data published online today in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies.

SMC Accepts Five New Medicines For Use In NHS Scotland

7/12/2016 04:03 pm

(European Pharmaceutical Review [UK]) July 11, 2016 - The Scottish Medicines Consortium (SMC) has accepted five new medicines for routine use in NHS Scotland.

Five Prime Announces FDA Orphan Drug Designation for FPA144 to Treat Gastric Cancer

7/5/2016 05:03 pm

(StreetInsider) July 5, 2016 - Five Prime Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to FPA144 for the treatment of gastric cancer, including cancer of the gastroesophageal junction in patients whose tumors overexpress FGFR2b.

Colon Cancer Screening: Five Things To Know

6/24/2016 05:33 pm

(Kaiser Health News) June 24, 2016 - It’s a predictable passage in life: Hit 50, get lots birthday cards with old-age jokes, a mailbox full of AARP solicitations — and a colonoscopy.

Five New Medicines Make It Onto The NHS

6/22/2016 06:59 pm

(PharmaTimes [UK]) June 22, 2016 - NICE has published new guidelines endorsing NHS use of five medicines, widening treatment options for some patients with lung cancer, high cholesterol, melanoma and the skin condition hidradentitis.

Five Early-Career Cancer Researchers Selected as Pew-Stewart Scholars

6/10/2016 04:06 pm

(The Pew Charitable Trusts) June 9, 2016 - The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2016 class of Pew-Stewart scholars for cancer research.

Five-year Results From Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)

6/6/2016 10:37 pm

(4-traders) June 6, 2016 - COMFORT-I data demonstrate that treatment with Jakafi resulted in a 31 percent reduction in the risk of death and sustained durable spleen volume reduction in patients with MF; these five-year data support previously published findings for Jakafi.

Five Prime Therapeutics Presents Updated Data From Phase 1 trial of Single-Agent FPA144 at 2016 ASCO Annual Meeting

6/6/2016 10:36 pm

(Yahoo! Finance) June 6, 2016 - Initial data show a 33% confirmed objective response rate, 77% disease control rate, and 12-week progression free survival of 67% in 9 FGFR2b+ gastric cancer patients available for analysis.

Improved Five-Year Survival For Pancreatic Cancer Patients

6/6/2016 07:15 pm

(University Of Liverpool) June 6, 2016 - An extra 13 percent of pancreatic cancer patients will live for at least five years when given a combination of chemotherapy drugs compared with standard treatment, according to the results of a Cancer Research UK trial led by the University of Liverpool.

Opinion: Macra: The Quiet Health-Care Takeover

6/1/2016 12:02 pm

(Wall Street Journal) May 31, 2016 - A 962-page rule puts the federal government between doctors and patients.

Five Storylines To Watch At ASCO

5/31/2016 04:06 pm

(Forbes) May 31, 2016 - Cancer R&D conferences, where companies and researchers get together to discuss fresh clinical trial results and scientific directions, happen almost every week. But this week, the cancer industry is getting ready for the biggest event of all, the American Society of Clinical Oncology (ASCO).

Prolonged Breath Holds of Over Five Minutes Could Help in Targeted Radiotherapy

5/12/2016 05:22 pm

(University of Birmingham [UK]) May 12, 2016 - Researchers at the University of Birmingham working with clinical teams at University Hospitals Birmingham NHS Foundation Trust have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath holds of over five minutes, opening the door for targeted radiotherapy to be administered with just one dose in each daily session.

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

5/3/2016 05:07 pm

(NASDAQ) May 2, 2016 - All hematological malignancies targeted by KTE-C19 development now covered by Orphan Drug Designations in U.S. and EU.

Stand Up To Cancer Supports "Innovation in Collaboration" in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards

5/2/2016 04:33 pm

(SU2C) May 2, 2016 - Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance "innovation in collaboration" among SU2C-affiliated scientists.

The DCIS Debate: New Study Finds that More Than Half of Women with Under Treated DCIS Recur within Five Years

4/15/2016 04:54 pm

(ASBrS) Apr 14, 2016 - More than half of all women with pre-cancerous ductal carcinoma in situ (DCIS) that is inadequately excised will develop a recurrence of the disease or invasive breast cancer within ten years of initial diagnosis, according to a new study presented this week at the Annual Meeting of the American Society of Breast Surgeons.

NCCN Foundation Awards Grants to Five Young Investigators

4/1/2016 04:43 pm

(NCCN) Apr 1, 2016 - The NCCN Foundation® has awarded grants to five young investigators from NCCN Member Institutions.

Novartis Heart-Failure Pill Hits Hurdles With Doctors

3/17/2016 11:05 am

(Wall Street Journal) Mar 16, 2016 - Novartis won regulatory approval last summer for a heart-failure pill, Entresto, that it called "one of the most remarkable drugs in cardiovascular medicine in the last several decades." Since then, it has faced a problem: getting doctors to prescribe it.

ACCC Annual Meeting: Five Key Takeaways

3/14/2016 05:20 pm

(ACCCBuzz) Mar 11, 2016 - Nearly 500 oncology professionals gathered in Washington, D.C., last week for the 42nd ACCC Annual Meeting, CANCERSCAPE.

GSK Ends Collaboration with Five Prime to Develop FP-1039

3/11/2016 06:20 pm

(Genetic Engineering & Biotechnology News) Mar 11, 2016 - GlaxoSmithKline is terminating its 5-year-old collaboration with Five Prime Therapeutics to develop the latter’s FP-1039 and returning its licensing rights to the cancer compound.

EBCC-10 NEWS: Five-Year Results Show 21-Gene Test Successfully Identifies Early Breast Cancer Patients Who Can Be Spared Chemotherapy

3/11/2016 05:16 pm

(ECCO) Mar 11, 2016 - Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis.

Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children

2/18/2016 01:02 pm

(Cancer MoonShot 2020) Feb 18, 2016 - In a press conference today, Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease.

Breast Cancer Surgical Option Carries Heightened Risk of Repeat Surgery

2/18/2016 11:05 am

(Weill Cornell) Feb 17, 2016 - Nearly one in four women with early-stage breast cancer who undergo a partial mastectomy will need a second surgery within 90 days, Weill Cornell Medicine investigators report in a new study.

NIH Researchers Identify Striking Genomic Signature Shared By Five Types Of Cancer

2/5/2016 05:28 pm

(NIH) Feb 5, 2015 - National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer.

NICE Backs Five Cancer Drugs, Spurns Cyramza

1/27/2016 06:34 pm

(BioCentury) Jan 26, 2016 - The U.K.'s NICE recommended a quintet of cancer drugs, including reversing a prior decision on Farydak panobinostat from Novartis AG; however, the agency snubbed stomach cancer compound Cyramza ramucirumab from Eli Lilly and Co.

NCCN Awards Research Grants to Five Investigators to Study Effectiveness of Enzalutamide in Various Cancers

1/13/2016 06:19 pm

(NCCN) Jan 13, 2016 - The NCCN Oncology Research Program has awarded five research grants to investigate the effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular, and prostate cancers.

Five Prime Therapeutics Provides Update on FP-1039 Clinical Program

1/11/2016 05:56 pm

(TheStreet) Jan 11, 2016 - Five Prime Therapeutics, Inc. today provided an update on GlaxoSmithKline's ongoing Phase 1b clinical trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non-small cell lung cancer (sqNSCLC) and mesothelioma.

Congress Ready To Give NIH Its Biggest Increase In 12 Years

12/16/2015 12:02 pm

(STAT) Dec 16, 2015 - The National Institutes of Health will get a $2 billion funding increase in the federal spending bill released early Wednesday, a big boost that could turn around the agency’s fortunes after years of stagnant budgets.

NIH-funded Trials Dip, Industry Trials On The Rise

12/16/2015 12:02 pm

(Fox News/Reuters) Dec 15, 2015 - Every year since 2006 in the U.S., the amount of new medical research in humans that’s funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.

FDA Approves Merck’s Surgery Drug Bridion

12/16/2015 12:02 pm

(Wall Street Journal) Dec 15, 2015 - U.S. health regulators have approved Merck & Co.’s sugammadex, an injectable drug to speed up a patient’s recovery following surgery.

Add-On Antimitotic Tx Promising in Glioblastoma

12/16/2015 12:02 pm

(MedPage Today/The Gupta Guide) Dec 15, 2015 - Adding tumor-treating fields (TTFields) to maintenance temozolomide (Temodar) chemotherapy significantly improved survival rates in patients with glioblastoma who had completed standard chemoradiation, according to results from a phase III trial.

Even in Basic Health Decisions, You Can’t Screen Out Politics

12/16/2015 12:02 pm

(The New York Times/The Upshot) Dec 14, 2015 - A panel of experts sets national standards for preventive care like mammograms, but it has not been immune to criticism from politicians.

Potential Prostate Cancer Treatment Developed In B.C. Gets Big Boost

12/16/2015 12:00 pm

(UBC [Canada]) Dec 15, 2015 - A potential treatment for advanced prostate cancer developed by the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.

A Banner Year for Moving ASCO Policy and Practice Agenda Forward

12/16/2015 11:05 am

(ASCO in Action) Dec 15, 2015 - During the past 12 months, an extraordinary level of activity and progress occurred in cancer-related policy and practice activities.

Congress Has Until December 16 to Pass Fiscal Year 2016 Spending Legislation

12/16/2015 11:05 am

(ASCO in Action) Dec 15, 2015 - Lawmakers now have until December 16 to pass an omnibus appropriations bill for Fiscal Year 2016.

Novartis Hires Harvard Star To Plug Gaps In Cancer Drug Arsenal

12/16/2015 11:05 am

(Reuters) Dec 16, 2015 - Pharmaceuticals giant Novartis is pinning its hopes on a 43-year-old Harvard cancer research star to help fill gaps in its immuno-oncology arsenal after "missing the boat" on some promising therapies.

Republicans Scrutinize FDA's Vouchers, Generic Drug Approvals

12/16/2015 11:05 am

(Bloomberg) Dec 15, 2015 - House Republicans are seeking information about priority vouchers awarded to makers of drugs for rare diseases, asking whether the Food and Drug Administration program is being taken advantage of.

New Therapies for Blood Cancers Emerging at Stunning Pace

12/16/2015 11:04 am

( Dec 15, 2015 - Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries in precision medicine and immunotherapy are leading to breakthrough therapies for a wide array of blood cancer patients.

What Jimmy Carter's Progress on Merck Drug Means For Other Cancer Patients

12/16/2015 11:04 am

(NJ Advance Media/ Dec 16, 2015 - When former president Jimmy Carter announced over the summer he had an advanced case of melanoma, or skin cancer, it was presumed the 91-year-old had a rocky road ahead.

The Children of China's Cancer Slum: Drug Costs Putting Young Lives at Risk

12/16/2015 11:04 am

(Bloomberg) Dec 15, 2015 - Life-and-death calculations aren’t that rare in a China that is home to the world’s largest number of cancer cases, and where patients can sometimes pay among the highest prices in the world for drug treatments.

Data Accrual Complete – CancerCare® Patient Access and Engagement Study

12/16/2015 11:04 am

(CancerCare) Dec 15, 2015 – CancerCare, a national nonprofit organization that provides free psychosocial support, education and financial assistance to anyone affected by cancer, has achieved its goal of enrolling more than 3,000 adults who have been diagnosed with cancer into its landmark Patient Access and Engagement study.

Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer

12/16/2015 11:03 am

(TheStreet) Dec 16, 2015 - Registrational, randomized, active-controlled Phase 3 study (ADVANCE) will study SPI-2012 as a treatment for chemotherapy-induced neutropenia in approximately 580 patients with breast cancer; the company expects to start the pivotal trial soon and plans to complete enrollment in 2017.

Five Factors Identify Subset of Patients With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab Treatment

12/15/2015 04:48 pm

(AACR) Dec 15, 2015 - Patients with advanced cervical cancer who were at intermediate and high risk of poor outcome, as assessed by the Moore criteria, gained survival benefit from having bevacizumab added to their chemotherapy regimen while those at low risk of poor outcome did not, according to results of a major objective of the phase III NRG Oncology-Gynecologic Oncology Group protocol 240 (GOG 240) clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Nivolumab Treatment in Melanoma Patients has Manageable Safety Profile, Additional Immunomodulatory Agents Do Not Affect Response Rates, Say Moffitt Cancer Center Researchers

5/29/2015 02:02 pm

(Moffitt) May 28, 2015 - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients.

Breast Cancer Guidelines Compared: ESMO vs NCCN

4/9/2015 12:00 am

(Medscape Medical News) Apr 9, 2015 - A comparison of breast cancer guidelines from two of the world's most prominent oncology organizations, the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), has revealed "substantial concordance," but also a host of "discrepancies."

Statement from ASH President David A. Williams, MD, on Introduction of the Patients’ Access to Treatments Act in the House of Representatives

3/27/2015 11:02 am

(ASH) Mar 25, 2015 - Today Representatives David McKinley (R-WV) and Lois Capps (D-CA) introduced the Patients’ Access to Treatments Act in the House of Representatives, an important first step toward removing the burden of excessive cost-sharing for Americans who need high-cost, specialty-tier medications.

Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting

12/7/2014 06:04 pm

(The Street) Dec 7, 2014 - Onconova Therapeutics, Inc. today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.

Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines

12/7/2014 06:04 pm

(Yahoo! Finance) Dec 6, 2014 - Takeda Pharmaceutical Company Limited today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology.

WILEX Subsidiary Heidelberg Pharma Extends Research Collaboration with Roche

10/14/2014 08:01 am

(4-traders) Oct 14, 2014 – WILEX AG today announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies.